±â»ç (Àüü 28,263°Ç) |
|
|
|
[Á¦¾à¡¤À¯Åë] Hair Care¿Í ºñŸ¹Î
´ëºÎºÐÀÇ ¸ð¹ßÁ¦Ç°¿¡ ´ëÇ¥ÀûÀ¸·Î ÷°¡µÇ´Â ÆÇÅ׳îÀº Á¤»óÀûÀÎ ÇÇºÎ¿Í ¸ð¹ßÀÇ ±¸¼º¼ººÐÀ¸·Î¼ ºñŸ¹Î B5ÀÌ´Ù. ÆÇÅ׳îÀº º¸½À°ú ¹ß¶õ½º¸¦ À¯ÁöÇÏ´Â ÄÁµð¼Å´× È¿°ú·Î ÀÎÇØ ¸¹Àº Á¦Ç°¿¡ À¯¿ëÇÏ°Ô ¾²ÀÌ°í ÀÖ´Ù. ÆÇÅ׳îÀº ¡®¸Å°³Ã¼¡¯¿Í ½ÀÀ±¼º ¹°Áú·Îµµ ÀÛ¿ëÇÒ ¼ö Àִµ¥,
hpharm(¾à±¹½Å¹®)
2002-09-11
|
|
|
|
[Á¦¾à¡¤À¯Åë] º£¸µ°ÅÀΰÖÇÏÀÓ - ¡®Æĸ¶Å桯
ÀλïÃßÃâ¹° G115 ÇÔÀ¯ ¡¦ ½ÅüÀû¤ýÁ¤½ÅÀû ±â´É ÁõÁøº£¸µ°ÅÀΰÖÇÏÀÓÀÌ ÀλïÃßÃâ¹° G115¸¦ ÇÔÀ¯ÇÑ Á¾ÇÕ¿µ¾çÁ¦ ¡®Æĸ¶Å桯À» »õ·Ó°Ô Ãâ½ÃÇÑ´Ù. Æĸ¶ÅæÀº G115¿Í ·¹½ÃÄ£, 20¿© °¡ÁöÀÇ ºñŸ¹Î, ¹Ì³×¶ö ±×¸®°í ¹Ì·®¿ø¼Ò°¡ È¿°úÀûÀ¸·Î ¹èÇÕµÈ Á¾ÇÕ¿µ¾çÁ¦·Î ÇöÀç
hpharm(¾à±¹½Å¹®)
2002-09-11
|
|
|
|
[Á¦¾à¡¤À¯Åë] Çٽɺ¹¾àÁöµµ - °¡½¿¾ÎÀÌ
À§»ê°ú´Ù ±âÀü ¼³¸íÇÏ°í »ýÈ°°³¼± ÁöµµÇؾß45¼¼ ³²¼ºÀÎ ±è¾¾´Â ¼Òȱ⠳»°ú¿¡¼ ÁøÂûÀ» ¹Þ°í ±Í°¡±æ¿¡ ó¹æÀüÀ» °¡Áö°í ¾à±¹À» ¹æ¹®ÇÏ¿´´Ù. Áö±Ý±îÁö ó¹æ ¹Þ¾Ò´ø ¾àÀÌ º¯°æµÇ¾ú±â ¶§¹®¿¡ ¡°¾àÀÌ ¹Ù²î¾ú³ª¿ä"¶ó°í È®ÀÎÀ» ÇÏ°í ´ÙÀ½°ú °°Àº Áú¹®À» ÇÏ¿´´Ù. ¼ÓÀÌ °è
hpharm(¾à±¹½Å¹®)
2002-09-10
|
|
|
|
[Á¦¾à¡¤À¯Åë] ½Å¿ë¹® ¾à»çÀÇ °íÇ÷¾Ð º¹¾àÁöµµ ¨ò - Indapamide [Èķ給½º Fludex, SR] Thiazide Diuretics
È¥¹Ì, ºÒ¾ÈÁ¤ÀÌ ³ªÅ¸³ª¸é ÁÖÄ¡ÀÇ¿Í »ó´ã ¡ÚÀúÄ®·ý Ç÷Áõ ÁõÈÄ=üÀ§¼º ÀúÇ÷¾Ð, ±â¸é, ±ÇÅÂ, ÇÇ·Î, ´Ù¸®°æ·Ã, ºó¸Æ, Çã¾à ¡ÚÃæºÐÇÑ ¼öºÐ ¼·Ãë=±Ý±â°¡ ¾Æ´Ï¸é ÇÏ·ç 2,000~3,000cc ¼öºÐ ¼·Ãë ->ƯÈ÷ °í·ÉÀÚ ÁÖÀÇ!=ü¾× ¼Õ½Ç·Î ÀÎÇÑ Ç÷¾×³óÃàÀ¸·Î Ç÷
hpharm(¾à±¹½Å¹®)
2002-09-10
|
|
|
|
|
|
[Á¦¾à¡¤À¯Åë] Çٽɺ¹¾àÁöµµ - °¡½¿¾ÎÀÌ
Àü¿¡ ±è¾¾¿¡°Ô ó¹æµÇ¾ú´ø NizatidineÀº LESÀÇ ¾Ð·Â ÀúÇϸ¦ °³¼±½ÃÅ°´Â ÀÛ¿ëµµ °âºñÇÏ°í ÀÖ´Â °ÍÀ¸·Î º¸°íµÇ¾ú´Ù.±è¾¾ÀÇ °æ¿ì °¡½¿¾ÎÀÌ°¡ °³¼±µÇÁö ¾Ê¾Ò´Ù°í ó¹æÀǻ簡 ÆÇ´ÜÇÏ¿´±â ¶§¹®¿¡ Nizatidineº¸´Ù Á¦»ê ÀÛ¿ëÀÌ °ÇÑ PPIÀÎ Omepraz
hpharm(¾à±¹½Å¹®)
2002-09-10
|
|
|
|
[Á¦¾à¡¤À¯Åë] ÇѾàƯ° 23 - Çãõ, õÁõ
ÀÌ ³ª°í ¶¡ÀÌ ³ª¸ç °¥ÁõÀ̳ª Âù °ÍÀ» ¸¶½Ã°í ½Í°í, ¾ó±¼ÀÌ ºÓÀ¸¸ç ÀÎÈÄ°¡ ¸¶¸£°í ¿ÀÁÜÀÌ ºÓÀ¸¸ç ´ëº¯ÀÌ ±»°í Å°¡ ȲÇϰųª ´ÏÇÏ°í ¸ÆÀÌ È°»èÇÏ´Ù.¤ýÁõÈÄ : »ç¿ÀÌ Æó¿¡ ½×¿© Áø¾×À» ÀÛ»óÇÏ¿© ´ãÀÌ Çü¼ºµÇ°í ¼÷°ÀÌ ¹«±ÇÇϸé Ç涱ÀÌ¸ç ±âħÇÏ°í ±â°¡ ¼Ú¾Æ¿À¸£¸ç
hpharm(¾à±¹½Å¹®)
2002-09-04
|
|
|
|
[Á¦¾à¡¤À¯Åë] ÇѾàƯ° 23 - Çãõ, õÁõ
½ÉÀ» Â÷°ÔÇÏ¿© ½É¾çÀÌ ÁøºÐµÇÁö ¾Ê°í Ç÷¸ÆÀÌ ¸·È÷¸ç ¾ó±¼ ÀÔ¼ú ¹ßÅé ¼³ÁúÀÌ Ã»ÀÚ»öÀ» ¶ç¸é ´Ü»ï¡¤È«È¡¤µµÀΡ¤Ãµ±ÃÀ» Àû´çÈ÷ °¡ÇÏ¿© È°Ç÷Ⱦî½ÃŲ´Ù.¸¸¾à õ¿ªÀÌ ½ÉÇÏ¿© ÀÔÀ» ¹ú¸®°í ¾î±ú°¡ À§·Î µé½â°Å¸®¸ç, ÄàµîÀÌ ºÎÇ®°í ¼û±æÀÌ ±ÞÇÏ¸ç ¾Ê¾Æ Àֱ⸸ ÇÏ°í, ´¯Áö
hpharm(¾à±¹½Å¹®)
2002-09-04
|
|
|
|
[Á¦¾à¡¤À¯Åë] ÇѾàƯ° 23 - Çãõ, õÁõ
ÀÚ±Ø ÇÇÇÏ°í ü·Âº¸°¤ý±â°ø ¿¬¸¶Çϸé È¿°úÀûÇã õ(1) ÆóÇã¤ýÁõÈÄ : Æó°¡ Çã¾àµÇ¾î ±â¸¦ ÁÖ°üÇÏÁö ¸øÇÑ´Ù. ±×·¯¹Ç·Î ¼ûÀÌ Â÷°í È£ÈíÀÌ ÀÚ¿¬½º·´Áö ¸øÇϸç ÀÎÈÄ¿¡ ÄÚ°í´Â ¼Ò¸®°¡ ÀÖ´Ù. Æó±â°¡ ºÎÁ·ÇÏ¿© ±âħ¼Ò¸®°¡ ³·°í ¾àÇÏ´Ù. ±â°¡ ÁøÀ» ¿îÈÇÏÁö ¸øÇϹǷΠ°´
hpharm(¾à±¹½Å¹®)
2002-09-04
|
|
|
|
[Á¦¾à¡¤À¯Åë] ¹Ì±¹¤ýij³ª´Ù ¾à»ç°í½Ã ¿¹»ó¹®Á¦
1. Which one of the following beta-adrenergic blocking agents has the graatest lipid solubility?1) esmolol 2)atenolol 3)pindolol 4)acebutolo
hpharm(¾à±¹½Å¹®)
2002-09-03
|
|
|
|
[Á¦¾à¡¤À¯Åë] ÁÖ¿äÁúȯ ó¹æ»ç·Ê - ºÒ¸éÁõ(Insomnia)
¼ö¸é À¯µµ ¾ÈµÇ¸é ¼ÓÈ¿¼º º¥Á¶µð¾ÆÁ¦ÇÉ°è ÀÀ¿ë¼ö¸éÀå¾ÖÁß °¡Àå ´ëÇ¥ÀûÀÎ °ÍÀÌ ºÒ¸éÁõÀÌ´Ù. ¼ö¸éÀº ÁßÃ߽Űæ°èÀÇ È°¼ºÈ, ¿¡³ÊÁöÀÇ ÀúÀå, ü¿ÂÁ¶Àý, °úºÎÈµÈ ³ú·ÎºÎÅÍ ±â¾ï»èÁ¦±â´É µîÀÌ ÀÖ´Ù. ÀÎü¿¡ ÇʼöÀûÀÎ ¼ö¸éÀÌ ºÎÁ·ÇÏ°Ô µÇ¸é ½ÅüÀû¡¤Á¤½ÅÀû ±â´É ÀúÇϸ¦ ÀÏ
hpharm(¾à±¹½Å¹®)
2002-09-03
|
|
|
|
[Á¦¾à¡¤À¯Åë] ÁÖ¿äÁúȯ ó¹æ»ç·Ê - ºÒ¸éÁõ(Insomnia)
Áõ°¡µÈ´Ù. È¿°ú¸¦ °è¼Ó À¯ÁöÇϱâ À§ÇØ ¾à¹°ÀÇ ¿ë·®À» Áõ°¡½ÃÅ°¸é °á±¹ ÃÖ°í¿ë·®À» º¹¿ëÇصµ º° È¿°ú°¡ ¾ø°Ô µÈ´Ù. ¾à¹°À» Áß´ÜÇÏ¸é ±Ý´ÜÇö»óÀ¸·Î ºÒ¸éÁõÀº ´õ ½ÉÇØÁö°í ´Ù½Ã ¸¹Àº ¿ë·®ÀÇ ¾à¹°À» º¹¿ëÇÏ°Ô µÇ´Â ¾Ç¼øȯÀÌ °è¼ÓµÈ´Ù. ±× °á°ú ¾à¹°¿¡ ´ëÇÑ ÀÇÁ¸¼ºÀÌ
hpharm(¾à±¹½Å¹®)
2002-09-03
|
|
|
|
|
|
|
|
[Á¦¾à¡¤À¯Åë] ¿¡µå¿Âºñ - ¸Þ°¡Á¡ÇÁ Ç÷¯½º
´ëÀÀÂ÷ Æò±Õ Ç¥ÁØÆíÂ÷ t Ç¥º»¼ö (¸í) À¯ÀÇÈ®·ü (¾çÂÊ) YGF251 Åõ¿©±º 1°³¿ùÈÄ-Åõ¿©Àü 23.738 35.014 2.712 16 .016 2°³¿ùÈÄ-Åõ¿©Àü 30.025 42.464 2.828 16 .013 À§¾à Åõ¿©±º
hpharm(¾à±¹½Å¹®)
2002-08-28
|
|
|
|
[Á¦¾à¡¤À¯Åë] ¿¡µå¿Âºñ - ¸Þ°¡Á¡ÇÁ Ç÷¯½º
F-I Åõ¿©¿¡ µû¸¥ ¼ºÀåÃËÁø °ñ°Ý±Ù Àç»ýÈ¿°ú, ¼¼Æ÷Áõ½ÄÈ¿°ú, Ç÷´ç·® Á¶Á¤È¿°ú, °ñ ¹«±âÁú ¹Ðµµ °³¼±È¿°ú µîÀÌ ÀÖ¾ú´Ù. µû¶ó¼ YGF251 Åõ¿©´Â IGF-IÀÇ ÁÖ¿äÀÛ¿ëÀÎ ¼ºÀå±â ¾Æµ¿ÀÇ ½ÅÀå Áõ°¡ È¿°ú»Ó¸¸ ¾Æ´Ï¶ó ¼ºÀο¡°Ô´Â Ç÷´ç·® °¨¼Ò, ¼¼Æ÷Áõ½Ä, ±Ù·Â°
hpharm(¾à±¹½Å¹®)
2002-08-28
|
|
|
|
[Á¦¾à¡¤À¯Åë] ¿¡µå¿Âºñ - ¸Þ°¡Á¡ÇÁ Ç÷¯½º
">2°³¿ù 275.6¡¾91.1 12.2 À§¾à Åõ¿©±º Åõ¿©Àü 280.0¡¾92.0 - 1°³¿ù 239.2¡¾63.5 -14.6 2°³¿ù 230.2¡¾53.8 -17.8 ¤ý Insulin ÇÔ·® º¯È¿Í ÀϹÝÈÇа˻çÀ§¾à Åõ¿©±ºÀÇ Insulin ÇÔ·®ÀÌ 36% °¨¼ÒÇÑ °Í
hpharm(¾à±¹½Å¹®)
2002-08-28
|
|
|
|
[Á¦¾à¡¤À¯Åë] ¿¡µå¿Âºñ - ¸Þ°¡Á¡ÇÁ Ç÷¯½º
Á÷Á¢ÀûÀÎ ÀÎÅͺ並 ÅëÇØ ºÎÀÛ¿ë ¹ß»ý°ú ƯÀÌ»çÇ×ÀÇ ¹ß»ý À¯¹«¸¦ È®ÀÎ °üÂûÇß´Ù.¤ý ÀÚ·áºÐ¼®°¢ ºÐ¼®Ç׸ñ¿¡ ´ëÇÑ °á°ú ºÐ¼®À» À§Çؼ ½ÇÇ豺°ú ´ëÁ¶±º °¢°¢¿¡ YGF251°ú À§¾àÀ» Åõ¿©ÇßÀ¸¸ç Åõ¿© Àü, 1°³¿ù Åõ¿© ÈÄ¿Í 2°³¿ù Åõ¿© ÈÄÀÇ ÃøÁ¤ °á°ú ºÐ¼®À» ½Ç½ÃÇß
hpharm(¾à±¹½Å¹®)
2002-08-28
|
|
|
|
[Á¦¾à¡¤À¯Åë] ¿¡µå¿Âºñ - ¸Þ°¡Á¡ÇÁ Ç÷¯½º
align="center">1°³¿ùÈÄ-Åõ¿©Àü -40.827 54.307 -2.912 15 .011 2°³¿ùÈÄ-Åõ¿©Àü -49.813 63.203 -3.052 15 .009 ¡Þ YGF251°ú À§¾à Åõ¿© ÈÄÀÇ Ç÷Áß Insulin ÇÔ·® º¯È ½ÇÇ豺 Åõ¿©±â°£(¿ù)
hpharm(¾à±¹½Å¹®)
2002-08-28
|
|
|
|
[Á¦¾à¡¤À¯Åë] ¿¡µå¿Âºñ - ¸Þ°¡Á¡ÇÁ Ç÷¯½º
nter">Ç¥º»¼ö (¸í) À¯ÈñÈ®·ü (¾çÂÊ) YGF251 Åõ¿©±º 1°³¿ù-Åõ¿©Àü 4.4225 1.6526 1.518 16 .150 À§¾à Åõ¿©±º 1°³¿ù-Åõ¿©Àü -4.3347 11.0866 -1.514 15 .152 °íÂû¿¬·É Áõ°¡¿¡ µû¸¥ ¼ºÀåÈ£¸£¸ó ºÐºñ °¨¼Ò
hpharm(¾à±¹½Å¹®)
2002-08-28
|
|
|